Patents by Inventor Diana Barea Roldan

Diana Barea Roldan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240415946
    Abstract: This disclosure relates to the field of RNA to treat lung cancer, in particular non-small-cell lung carcinoma (NSCLC). Lung cancer is the third most frequent malignancy in women and the second most frequent malignancy in men. NSCLC accounts for about 85% of all lung cancers. Disclosed herein are compositions, uses, and methods for treatment of lung cancers. Administration of therapeutic RNAs to a patient having lung cancer disclosed herein can reduce tumor size, prolong time to progressive disease, and/or protect against metastasis and/or recurrence of the tumor and ultimately extend survival time.
    Type: Application
    Filed: October 10, 2022
    Publication date: December 19, 2024
    Inventors: Ugur SAHIN, David WEBER, Carina WALTER, Diana BAREA ROLDÁN, Ruprecht KUNER, Melanie HEIN, Martin SUCHAN,, Vetena KISSLER, Lena Mareen KRANZ
  • Publication number: 20230114808
    Abstract: Disclosed herein are compositions, uses, and methods for treatment of prostate cancers.
    Type: Application
    Filed: March 11, 2020
    Publication date: April 13, 2023
    Inventors: David WEBER, Carina WALTER, Diana BAREA ROLDAN, Ruprecht KUNER, Elif DIKEN, Martin SUCHAN, Stefania GANGI MAURICI, Ugur SAHIN
  • Publication number: 20220257631
    Abstract: Disclosed herein are compositions, uses, and methods for treatment of ovarian cancers. In one aspect, provided herein is a composition or medical preparation comprising at least one RNA, wherein the at least one RNA encodes the following amino acid sequences: (i) an amino acid sequence comprising claudin 6 (CLDN6), an immunogenic variant thereof, or an immunogenic fragment of the CLDN6 or the immunogenic variant thereof; (ii) an amino acid sequence comprising p53, an immunogenic variant thereof, or an immunogenic fragment of the p53 or the immunogenic variant thereof; and (iii) an amino acid sequence comprising Preferentially Expressed Antigen In Melanoma (PRAME), an immunogenic variant thereof, or an immunogenic fragment of the PRAME or the immunogenic variant thereof.
    Type: Application
    Filed: May 20, 2020
    Publication date: August 18, 2022
    Inventors: Ugur SAHIN, David WEBER, Carina WALTER, Diana BAREA ROLDAN, Ruprecht KUNER, Meike WAGNER, Martin SUCHAN, Stefania GANGI MAURICI, Stefanie HUBICH-RAU, René BECKER
  • Patent number: 10429392
    Abstract: The present invention relates to the identification of nucleic acid and amino acid sequences that are characteristic of tumor tissues, in particular tumors of the central nervous system (CNS) such as glioma, in particular glioblastoma and which represent targets for therapy or diagnosis of tumor diseases in a subject.
    Type: Grant
    Filed: October 19, 2015
    Date of Patent: October 1, 2019
    Assignees: BIONTECH RNA PHARMACEUTICALS GMBH, TRON—TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITAT
    Inventors: Ugur Sahin, Claudia Paret, Christian Bender, Kirsten Vormbrock, Diana Barea Roldan, Stefanie Hubich, Christoph Hartmann
  • Publication number: 20170276681
    Abstract: The present invention relates to the identification of nucleic acid and amino acid sequences that are characteristic of tumor tissues, in particular tumors of the central nervous system (CNS) such as glioma, in particular glioblastoma and which represent targets for therapy or diagnosis of tumor diseases in a subject.
    Type: Application
    Filed: October 19, 2015
    Publication date: September 28, 2017
    Inventors: Ugur Sahin, Claudia Paret, Christian Bender, Kirsten Vormbrock, Diana Barea Roldan, Stefanie Hubich, Christoph Hartmann